Adam Koppel, the Chairman of our board of directors since August 2020, initially joined Bain Capital in 2003 and is a Managing Director on the investment team and a member of the internal investment committee of Bain Capital Life Sciences. Prior to co-founding Bain Capital Life Sciences in 2016, Dr. Koppel worked within the healthcare vertical of Bain Capital Public Equity from 2003 to 2014. Dr. Koppel also served as Executive Vice President of Corporate Development and Chief Strategy Officer of Biogen (Nasdaq: BIIB) from 2014 to 2016, and as a director of ViaCyte from November 2018 to January 2021. Dr. Koppel currently serves on the boards of directors of Aptinyx (Nasdaq: APTX), Cerevel Therapeutics Holdings (Nasdaq: CERE, CEREW), Dicerna Pharmaceuticals (Nasdaq: DRNA), Solid Biosciences (Nasdaq: SLDB), which are portfolio companies of Bain Capital Life Sciences, and public company Foghorn Therapeutics (Nasdaq: FHTX). Prior to initially joining Bain Capital, Dr. Koppel was an Associate Principal at McKinsey & Co, where he served a variety of healthcare companies. Dr. Koppel earned an MD and PhD in neuroscience from the University of Pennsylvania School of Medicine, an MBA from the University of Pennsylvania, where he was a Palmer Scholar, and an AB and AM, magna cum laude, in history and science from Harvard University.